In a study by Gradishar et al (1997), 43 stage III patients received four cycles of docetaxel 100 mg m−2 on a 3-weekly schedule, followed by surgery, then four cycles of adjuvant doxorubicin plus cyclophosphamide, and also tamoxifen if the tumour was hormone-receptor positive or the patient was aged >50 years. Here, NR4A1 is linked to neoplasm.